| scholarly article | Q13442814 |
| P2093 | author name string | Charbel E-H Moussa | |
| Irina Lonskaya | |||
| Michaeline L Hebron | |||
| Fernando Pagan | |||
| Paul Olopade | |||
| Sandra T Selby | |||
| P2860 | cites work | The chemokine fractalkine in patients with severe traumatic brain injury and a mouse model of closed head injury | Q80969187 |
| Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus | Q21245234 | ||
| RFLAT-1: a new zinc finger transcription factor that activates RANTES gene expression in T lymphocytes | Q22008771 | ||
| Fractalkine-mediated endothelial cell injury by NK cells | Q22253856 | ||
| Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities | Q24295053 | ||
| VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection | Q24302846 | ||
| Parkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer model | Q24305472 | ||
| Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion | Q24311291 | ||
| c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease | Q24318974 | ||
| Isolation of interleukin 2-induced immediate-early genes | Q24563249 | ||
| Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers | Q24620129 | ||
| Interferon-gamma and interleukin-4 reciprocally regulate CD8 expression in CD8+ T cells | Q24643390 | ||
| Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity | Q24650569 | ||
| Human immune interferon gene is located on chromosome 12 | Q24683596 | ||
| DNA array analysis of interleukin-2-regulated immediate/early genes | Q24799770 | ||
| Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model | Q28115206 | ||
| Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models | Q28119018 | ||
| Inflammation and Alzheimer's disease | Q28138617 | ||
| Transcriptional regulation of RANTES expression in T lymphocytes | Q28141636 | ||
| Dysregulation of the IgE/Fc epsilon RI network in HIV-1 infection | Q28142215 | ||
| Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the central nervous system | Q28142879 | ||
| Chemokines and disease | Q28200068 | ||
| Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils | Q28205971 | ||
| Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation | Q28240071 | ||
| Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant | Q28252699 | ||
| Regulation of interferon-gamma during innate and adaptive immune responses | Q28256001 | ||
| Highly regionalized neuronal expression of monocyte chemoattractant protein-1 (MCP-1/CCL2) in rat brain: evidence for its colocalization with neurotransmitters and neuropeptides | Q28262316 | ||
| Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis | Q28268096 | ||
| Role of CCL2 (MCP-1) in traumatic brain injury (TBI): evidence from severe TBI patients and CCL2-/- mice | Q28268523 | ||
| Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells | Q28270680 | ||
| Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease | Q28275105 | ||
| CC chemokines induce the generation of killer cells from CD56+ cells | Q28277084 | ||
| The emerging role for chemokines in epilepsy | Q28285051 | ||
| Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro | Q28291482 | ||
| A new class of membrane-bound chemokine with a CX3C motif | Q28303204 | ||
| Expression of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 after focal cerebral ischemia in the rat | Q28307447 | ||
| A human T cell-specific molecule is a member of a new gene family | Q28307933 | ||
| Control of microglial neurotoxicity by the fractalkine receptor | Q28513748 | ||
| Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway | Q28571359 | ||
| Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia | Q28573077 | ||
| Obesity induces a phenotypic switch in adipose tissue macrophage polarization | Q29547686 | ||
| Ranibizumab for neovascular age-related macular degeneration | Q29617549 | ||
| Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases | Q30157679 | ||
| Tau and src family tyrosine kinases | Q30160372 | ||
| Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease | Q30581719 | ||
| Nitrated alpha-synuclein and microglial neuroregulatory activities | Q33315262 | ||
| Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance | Q33376325 | ||
| Altered subcellular distribution of c-Abl in Alzheimer's disease | Q33429538 | ||
| A mechanism for the initiation of allergen-induced T helper type 2 responses | Q34010133 | ||
| Interleukins for B lymphocytes | Q34056680 | ||
| Regulation of Tau Pathology by the Microglial Fractalkine Receptor | Q34179654 | ||
| Human IL-3 (multi-CSF): identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. | Q34180710 | ||
| CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. | Q34254575 | ||
| An update on dual Src/Abl inhibitors | Q34270677 | ||
| Targeting interleukin-4 in asthma: lost in translation? | Q34271232 | ||
| Regulation of T cell differentiation: in vitro induction of 20 alpha-hydroxysteroid dehydrogenase in splenic lymphocytes from athymic mice by a unique lymphokine. | Q34274355 | ||
| Role of VEGF in developmental angiogenesis and in tumor angiogenesis in the brain. | Q34305062 | ||
| Microglia in neurodegeneration: molecular aspects | Q34349294 | ||
| Interleukin-4 receptor signaling pathways in asthma pathogenesis | Q34355560 | ||
| VEGF at the neurovascular interface: therapeutic implications for motor neuron disease | Q34539899 | ||
| CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. | Q34576624 | ||
| CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-β phagocytosis | Q34796584 | ||
| Ubiquitination increases parkin activity to promote autophagic α-synuclein clearance | Q35080740 | ||
| CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. | Q35213298 | ||
| Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain. | Q35949689 | ||
| Microglia as a potential bridge between the amyloid beta-peptide and tau. | Q36024909 | ||
| Neuronal c-Abl activation leads to induction of cell cycle and interferon signaling pathways | Q36369785 | ||
| Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues | Q36742483 | ||
| Decreased parkin solubility is associated with impairment of autophagy in the nigrostriatum of sporadic Parkinson's disease | Q36746491 | ||
| Immunological features of alpha-synuclein in Parkinson's disease | Q37232067 | ||
| c-Abl in neurodegenerative disease | Q37897502 | ||
| Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance | Q38615100 | ||
| Interleukin-2: inception, impact, and implications | Q39603037 | ||
| Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. | Q39746633 | ||
| Wild type and P301L mutant Tau promote neuro-inflammation and α-Synuclein accumulation in lentiviral gene delivery models | Q39994322 | ||
| Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease | Q40098160 | ||
| Synuclein activates microglia in a model of Parkinson's disease | Q40126232 | ||
| Fractalkine signaling and Tau hyper-phosphorylation are associated with autophagic alterations in lentiviral Tau and Aβ1-42 gene transfer models | Q40392115 | ||
| Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. | Q40398116 | ||
| Fractalkine and fractalkine receptors in human neurons and glial cells | Q40717328 | ||
| Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance | Q42003730 | ||
| Tyrosine kinase inhibition facilitates autophagic SNCA/α-synuclein clearance | Q42220307 | ||
| In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease | Q42484469 | ||
| Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration | Q42505583 | ||
| Interleukin-2 induction of T-cell G1 progression and c-myb expression | Q42521592 | ||
| Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models | Q42711308 | ||
| Induction of vascular endothelial growth factor receptor-3 mRNA in glial cells following focal cerebral ischemia in rats | Q42943835 | ||
| Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. | Q44820147 | ||
| Manganese potentiates in vitro production of proinflammatory cytokines and nitric oxide by microglia through a nuclear factor kappa B-dependent mechanism | Q45188778 | ||
| Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease | Q46404588 | ||
| New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease | Q48003429 | ||
| Production and neuroprotective functions of fractalkine in the central nervous system | Q48258224 | ||
| Increased intrathecal release of soluble fractalkine in HIV-infected patients | Q48363839 | ||
| Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein | Q48581887 | ||
| Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse | Q49160789 | ||
| Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons. | Q54703574 | ||
| The interleukin-2 T-cell system: a new cell growth model. | Q55062562 | ||
| Obituaries: Mrs Annie Isabella Anslow, Eileen Georgina Sherrard | Q66898562 | ||
| CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system | Q73197840 | ||
| P304 | page(s) | 259 | |
| P577 | publication date | 2014-09-01 | |
| P1433 | published in | Journal of Clinical & Cellular Immunology | Q27723807 |
| P1476 | title | Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy | |
| P478 | volume | 5 |
| Q37137895 | Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration |
| Q53371980 | Amelioration of experimentally induced diabetic nephropathy and renal damage by nilotinib. |
| Q42291075 | An enhanced recombinant amino-terminal acetylation system and novel in vivo high-throughput screen for molecules affecting α-synuclein oligomerisation. |
| Q90293280 | Biomedical Implications of Autophagy in Macromolecule Storage Disorders |
| Q41634845 | Microglial-mediated PDGF-CC activation increases cerebrovascular permeability during ischemic stroke. |
| Q64938069 | Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration. |
| Q58737028 | Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches |
| Q38840128 | Nilotinib - Differentiating the Hope from the Hype |
| Q37225128 | Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies |
| Q92007135 | Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial |
| Q64988558 | Nilotinib: A Tyrosine Kinase Inhibitor Mediates Resistance to Intracellular Mycobacterium Via Regulating Autophagy. |
| Q47860695 | Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy |
| Q64104966 | Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease |
| Q34554401 | Recent advances in treating Parkinson's disease |
| Q97527711 | Targeting dementias through cancer kinases inhibition |
| Q38752798 | Tyrosine kinase inhibition reverses TDP-43 effects on synaptic protein expression, astrocytic function and amino acid dis-homeostasis |
Search more.